Abstract
Safety and Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion for Parkinson’s disease: Three-Year Data from the Open-Label BeyoND study (PL4.003)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
